The weight of interleukin-6 in B cell-related autoimmune disorders

被引:74
作者
Youinou, Pierre
Jamin, Christophe
机构
[1] Univ Europeenne Bretagne, Brest, France
[2] Univ Brest, EA Immunol & Pathol 2216, IFR SclnBioS 148, F-29609 Brest, France
[3] CHU Brest, F-29285 Brest, France
关键词
Interleukin-6; B lymphocyte; Rheumatoid arthritis; Systemic lupus erythematosus; Sjogren's syndrome; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ANTI-INTERLEUKIN-6 RECEPTOR ANTIBODY; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; SJOGRENS-SYNDROME; IL-6; EXPRESSION; GENE; DISEASES;
D O I
10.1016/j.jaut.2009.02.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Interleukin (IL)-6 is a prevailing factor of polyclonal B-cell activation of B cells, and thereby of their tolerance breach. Its receptor (R) complex consists of a transducing unit, and a membrane-bound or soluble protein. Many activities ascribed to this cytokine are generated by the soluble IL-6R. Evidence has however been gleaned in autoimmune diseases that the system is instrumental in rheumatoid arthritis (RA), Sjogren's syndrome and systemic lupus erythematosus (SLE). To gain insight into the understanding of the mechanisms behind these observations, a prime example is the recombination-activating gene (Rag) machinery in B lymphocytes. It is interesting that the expression of Rags is favored by IL-6, and repressed by anti-IL-6R antibody (Ab) in RA and SLE. Not surprisingly. clinical benefits are reported in the treatment of autoimmune disorders with anti-IL-6R Ab, and other perspectives about to be open in biotherapy. (C) 2009 Published by Elsevier Ltd.
引用
收藏
页码:206 / 210
页数:5
相关论文
共 58 条
[1]
BIOLOGY OF MULTIFUNCTIONAL CYTOKINES - IL-6 AND RELATED MOLECULES (IL-1 AND TNF) [J].
AKIRA, S ;
HIRANO, T ;
TAGA, T ;
KISHIMOTO, T .
FASEB JOURNAL, 1990, 4 (11) :2860-2867
[2]
Repression of the IL-6 gene is associated with hypermethylation [J].
Armenante, F ;
Merola, M ;
Furia, A ;
Palmieri, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 258 (03) :644-647
[3]
B cell targeted therapy in autoimmunity [J].
Blank, Miri ;
Shoenfeld, Yehuda .
JOURNAL OF AUTOIMMUNITY, 2007, 28 (2-3) :62-68
[4]
The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases [J].
Boren, Eric J. ;
Cheema, Gurtej S. ;
Naguwa, Stanley M. ;
Ansari, Aftab A. ;
Gershwin, M. Eric .
JOURNAL OF AUTOIMMUNITY, 2008, 30 (1-2) :90-98
[5]
Chinese Americans and American society [J].
Chen Changfu .
CHINESE STUDIES IN HISTORY, 2008, 41 (03) :3-22
[6]
Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis - A randomized, double-blind, placebo-controlled, dose-escalation trial [J].
Choy, EHS ;
Isenberg, DA ;
Garrood, T ;
Farrow, S ;
Ioannou, Y ;
Bird, H ;
Cheung, N ;
Williams, B ;
Hazleman, B ;
Price, R ;
Yoshizaki, K ;
Nishimoto, N ;
Kishimoto, T ;
Panayi, GS .
ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3143-3150
[7]
New cytokine targets in inflammatory rheumatic diseases [J].
Connell, Laura ;
McInnes, Iain B. .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2006, 20 (05) :865-878
[8]
SOCS regulation of the JAK/STAT signalling pathway [J].
Croker, Ben A. ;
Kiu, Hiu ;
Nicholson, Sandra E. .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2008, 19 (04) :414-422
[9]
FOX RI, 1994, J IMMUNOL, V152, P5532
[10]
GORDON C, 1991, CLIN EXP IMMUNOL, V86, P145